Prolymphocytic Leukemia — Trials

Prolymphocytic Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

95 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 11
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: City of Hope Medical Center
Termination share: 25%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (18)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02029443	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia	active not recruiting	Phase 1 / Phase 2	306	Acerta Pharma BVINDUSTRY	3	May 5, 2026	clinicaltrials
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	active not recruiting	Phase 1	18	City of Hope Medical CenterOTHER	1	Apr 27, 2026